Epicatechin Inhibits FGFR3 Signaling to Restore Bone Growth
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with FGFR3-related chondrodysplasias face challenges due to delayed diagnosis, inadequate treatments, and limited access to care, largely because current therapies are ineffective in addressing the abnormal activation of the FGFR3 receptor, which leads to skeletal and developmental issues.
Innovation Solution
Administration of a therapeutically effective amount of substantially pure (−)-epicatechin, which inhibits FGFR3 signaling pathways, thereby treating FGFR3-related chondrodysplasias by targeting the constitutively active mutant receptors responsible for these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for FGFR3-related chondrodysplasias, then treatment accessibility is maintained, but treatment effectiveness is insufficient due to inability to address abnormal FGFR3 activation
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of epicatechin to create analogs with enhanced FGFR3 inhibitory activity. Specifically, the invention modifies the hydroxyl groups and ring structures of epicatechin to optimize binding affinity to the FGFR3 tyrosine kinase domain, thereby improving treatment effectiveness while maintaining selectivity for FGFR3-related chondrodysplasias
Solution Approach 2:
The patent uses epicatechin and its analogs as intermediary compounds that mediate between the FGFR3 receptor and downstream signaling pathways. These compounds act as tyrosine kinase inhibitors that block the abnormal signaling cascade initiated by FGFR3 mutations, thereby translating molecular inhibition into therapeutic effect without requiring direct modification of the mutant receptor
2Reliability
If FGFR3 signaling is strongly inhibited to improve treatment efficacy, then bone growth improvement increases, but risk of off-target effects and toxicity increases
Solution Approach 1:
The patent applies local quality by designing epicatechin analogs with specific structural modifications that enhance binding selectivity to FGFR3 while minimizing interaction with other receptor tyrosine kinases. The invention optimizes specific functional groups (such as hydroxyl positions and ring substitutions) to create a localized binding profile that is highly specific to FGFR3, thereby improving therapeutic efficacy while reducing off-target effects
Solution Approach 2:
The patent employs partial action by using epicatechin and its analogs as moderate-strength tyrosine kinase inhibitors that achieve sufficient FGFR3 suppression at clinically achievable doses without complete blockade of all RTK pathways. This approach maintains enough residual signaling to avoid severe off-target effects while providing therapeutic benefit through selective inhibition of the mutant FGFR3-driven pathology
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of (−)-epicatechin effectively reduces FGFR3 signaling, leading to improved bone growth and reduced severity of symptoms in FGFR3-related chondrodysplasias, as demonstrated by increased femur length and modified growth plate cartilage expression, providing a potential therapeutic option for these rare diseases.
Implementation Method 1
The mutation, which produce an increase of FGFR3 function, affects many tissues... As other RTKs, the binding of the ligand, that is fibroblast growth factors (FGFs), leads to dimerization and transautophosphorylation, resulting in the stimulation of its tyrosine kinase activity
Data Source
AI summary
FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (−)-epicatechin from T. cacao and showed that (−)-epicatechin treatment significantly increases the length of the Fgfr3Y367C/+ femurs comparing to Fgfr3+/+ femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (−)-epicatechin for the treatment of FGFR3-related chondrodysplasias.